IL1B and type 1 diabetes mellitus: The results obtained allow for the hypothesis of a potential role of IL-1β as a therapeutic target in the early stages of T1DM, where the actual treatments are focused on the pharmacological abrogation of IL-1β action and reducing T1DM progression.